Cognition Therapeutics

About Cognition Therapeutics

Cognition Therapeutics, Inc. is a company focused on preventing the progression of central nervous system (CNS) disorders by targeting cellular damage response mechanisms. Their mission is to protect neurons and fight neurodegenerative diseases such as Alzheimer's disease and dementia with Lewy bodies through innovative therapeutic approaches.

Products & Services

Zervimesine (CT1812):A once-daily, oral, small-molecule drug designed to rescue trafficking deficits in neurons, helping maintain normal brain function and potentially slowing the progression of Alzheimer's disease and dementia with Lewy bodies by binding to receptors that regulate these functions.

Zervimesine (CT1812)

Specialties

Neurodegenerative Diseases Alzheimer's Disease Dementia with Lewy Bodies CNS Disorder Therapeutics Small-Molecule Drug Development Neurodegenerative diseases Alzheimer’s disease Dementia with Lewy bodies Synaptic protection

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Philanthropic Donation T: - FT: Philanthropic Donation	A: 200000000 MR: - FA: nearly $200 million FAN: 200000000	D: 2026-05-14 FD: 2026-05-14	1 investors
2	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 30000000 MR: - FA: approximately $30 million FAN: 30000000	D: 2025-09-02 FD: 2025-09-02	2 investors
3	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 30000000 MR: - FA: approximately $30 million FAN: 30000000	D: 2025-08-27 FD: 2025-08-27	1 investors
4	RT: Public Offering T: - FT: Public Offering	A: 11500000 MR: - FA: approximately $11.5 million FAN: 11500000	D: 2024-03-14 FD: 2024-03-14	1 investors
5	RT: Public Offering T: - FT: Public Offering	A: 11500000 MR: - FA: $11.5 Million FAN: 11500000	D: 2024-03-11 FD: 2024-03-11	1 investors

Philanthropic Donation Latest

2026-05-14

$200.0M

1 investor (Pro only)

Registered Direct Offering 2025-09-02

$30.0M

Registered Direct Offering 2025-08-27

$30.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Susan Catalano

Co-founder

L

Lisa Ricciardi

Chief Executive Officer

A

Anthony Caggiano

Chief Medical Officer

J

John Doyle

Chief Financial Officer

A

Anita Cornet

Head of Quality

T

Theresa Devins

Vice President, Clinical Operations

View 22 more team members with Pro

Unlock Full Team Directory

Recent News